Brieuc SAUTOIS

Clinical Professor

CHU de Liège - Hôpital du Sart Tilman

Belgium

Research Interests

Explore related searches

Professors in Belgium Professors in Cancer Biology Cancer Biology professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Brieuc SAUTOIS is a Clinical Professor at CHU de Liège - Hôpital du Sart Tilman in Belgium. His research focuses on oncology, particularly in the areas of prostate cancer and muscle-invasive bladder cancer, as demonstrated in his recent publications. He has contributed to significant studies involving neoadjuvant therapies, circulating tumor DNA, and therapeutic strategies for advanced metastatic cancers.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Bram De Laere

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brieuc SAUTOIS

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Characterization of exclusive rib lesions detected by [68Ga]Ga-PSMA-11 PET/CT

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique

Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

Using, <sup>68</sup>Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Oncological patients' reactions to COVID ‐19 pandemic: A single institution prospective study

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer

Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene

Collaborators (1)

Bram De Laere

Make your next move.